文献速递血栓与止血白血病

聚乙二醇化门冬酰胺酶(PEG-ASP)相较天然L-ASP相关的静脉血栓栓塞发生率:成人急性淋巴细胞白血病中基于ASP方案的回顾性分析

Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
PubMed 文献 · Br J Haematol · 2023-02-16

该单中心回顾性队列纳入2011–2021年245例费城染色体阴性成人急性淋巴细胞白血病患者,比较天然L-ASP(175例)与PEG-ASP(70例)相关静脉血栓栓塞发生率,诱导期PEG-ASP组VTE发生率28.57% vs L-ASP组10.29%(P=0.0035;OR 3.35,95%CI 1.51–7.39),强化期PEG-ASP组34.37% vs L-ASP组13.64%(P=0.0096;OR 3.96,95%CI 1.57–9.96),尽管给予了预防性抗凝。

要点

  • 诱导期PEG-ASP组VTE发生率28.57%(20/70)vs L-ASP组10.29%(18/175),OR 3.35(95%CI 1.51–7.39),P=0.0035。
  • 强化期PEG-ASP组VTE发生率34.37%(11/32)vs L-ASP组13.64%(18/132),OR 3.96(95%CI 1.57–9.96),P=0.0096。
  • 尽管给予预防性抗凝,PEG-ASP仍与更高的VTE发生率相关,作者提出需进一步VTE减轻策略。

核心结论

  • 与天然L-ASP相比,PEG-ASP在诱导期和强化期均与更高的VTE发生率相关,尽管给予了预防性抗凝。
  • 作者提出,尤其对接受PEG-ASP的成人ALL患者,需要进一步的VTE减轻策略。

研究设计与样本

  • 单中心回顾性队列研究,纳入2011–2021年245例费城染色体阴性成人ALL患者。
  • L-ASP组175例(2011–2019年),PEG-ASP组70例(2018–2021年)。

主要发现

  • 诱导期L-ASP组VTE发生率10.29%(18/175)vs PEG-ASP组28.57%(20/70)(P=0.0035;OR 3.35,95%CI 1.51–7.39),校正线类型、性别、VTE史、诊断时血小板。
  • 强化期L-ASP组VTE发生率13.64%(18/132)vs PEG-ASP组34.37%(11/32)(P=0.0096;OR 3.96,95%CI 1.57–9.96,多因素分析)。

关键数值与推荐

  • 诱导期:PEG-ASP组VTE 28.57%(20/70)vs L-ASP组10.29%(18/175),OR 3.35(95%CI 1.51–7.39),P=0.0035。
  • 强化期:PEG-ASP组VTE 34.37%(11/32)vs L-ASP组13.64%(18/132),OR 3.96(95%CI 1.57–9.96),P=0.0096。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism (VTE) is a well-known complication in patients with acute lymphoblastic leukaemia (ALL) receiving asparaginase (ASP)-based chemotherapy, including the ASP-intensive Dana-Farber Cancer Institute (DFCI) 91-01 protocol for adults. Since 2019, native L-ASP is no longer available in Canada and was replaced by pegylated (PEG)-ASP. To determine whether the incidence of VTE has changed since switching from L-ASP to PEG-ASP, we conducted a single-centred retrospective cohort study. We included 245 adult patients with Philadelphia chromosome negative ALL between 2011 and 2021, with 175 from the L-ASP group (2011-2019) and 70 from the PEG-ASP group (2018-2021). During Induction, 10.29% (18/175) of patients who received L-ASP developed VTE, whereas 28.57% (20/70) of patients who received PEG-ASP developed VTE (p = 0.0035; odds ratio [OR] 3.35, 95% confidence interval [CI] 1.51-7.39), after adjusting for line type, gender, history of VTE, platelets at diagnosis. Similarly, during Intensification, 13.64% (18/132) of patients had VTE on L-ASP while 34.37% (11/32) of patients on PEG-ASP developed VTE (p = 0.0096; OR 3.96, 95% CI 1.57-9.96 with multivariable analysis). We found that PEG-ASP is associated with a higher incidence of VTE compared to L-ASP, both during Induction and Intensification, despite the administration of prophylactic anticoagulation. Further VTE mitigation strategies are needed in particular for adult patients with ALL receiving PEG-ASP.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chen R, Atenafu EG, Seki J, et al. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2023. PMID: 36794878. doi:10.1111/bjh.18683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。